225 related articles for article (PubMed ID: 10370912)
1. Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease.
Calne DB
J Neural Transm Suppl; 1999; 56():185-92. PubMed ID: 10370912
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacology of dopamine agonists in Parkinson's disease.
Lange KW
Drugs Aging; 1998 Nov; 13(5):381-9. PubMed ID: 9829165
[TBL] [Abstract][Full Text] [Related]
3. Ropinirole and pramipexole, the new agonists.
Hobson DE; Pourcher E; Martin WR
Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Nyholm D
Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
[TBL] [Abstract][Full Text] [Related]
6. Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?
Rascol O
J Neural Transm Suppl; 1999; 55():33-45. PubMed ID: 10335491
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Parkinson's disease should begin with a dopamine agonist.
Montastruc JL; Rascol O; Senard JM
Mov Disord; 1999 Sep; 14(5):725-30. PubMed ID: 10495032
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease.
Fariello RG
Drugs; 1998; 55 Suppl 1():10-6. PubMed ID: 9483165
[TBL] [Abstract][Full Text] [Related]
9. Dopamine agonists and Parkinson's disease.
Burton K; Calne DB
Clin Neurol Neurosurg; 1984; 86(3):172-7. PubMed ID: 6091965
[TBL] [Abstract][Full Text] [Related]
10. [The therapeutic plasma concentrations of antiparkinson dopamine agonists and their in vitro pharmacology at dopamine receptors].
Tadori Y; Kobayashi H
Nihon Shinkei Seishin Yakurigaku Zasshi; 2014 Nov; 34(5-6):127-32. PubMed ID: 25536763
[TBL] [Abstract][Full Text] [Related]
11. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
Linazasoro G;
Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
[TBL] [Abstract][Full Text] [Related]
12. Pergolide in the treatment of patients with early and advanced Parkinson's disease.
Bonuccelli U; Colzi A; Del Dotto P
Clin Neuropharmacol; 2002; 25(1):1-10. PubMed ID: 11852289
[TBL] [Abstract][Full Text] [Related]
13. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
Bonuccelli U; Del Dotto P; Rascol O
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
[TBL] [Abstract][Full Text] [Related]
14. Comparing dopamine agonists in Parkinson's disease.
Bonuccelli U
Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S13-9. PubMed ID: 15180133
[TBL] [Abstract][Full Text] [Related]
15. New pharmacotherapy for Parkinson's disease.
Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK
Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447
[TBL] [Abstract][Full Text] [Related]
16. Dopamine agonists used in the treatment of Parkinson's disease and their selectivity for the D1, D2, and D3 dopamine receptors in human striatum.
De Keyser J; De Backer JP; Wilczak N; Herroelen L
Prog Neuropsychopharmacol Biol Psychiatry; 1995 Nov; 19(7):1147-54. PubMed ID: 8787038
[TBL] [Abstract][Full Text] [Related]
17. [The role of dopaminagonists in the treatment of Parkinson's disease].
Ransmayr G
Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
[TBL] [Abstract][Full Text] [Related]
18. Dihydroergocriptine in Parkinson's disease: clinical efficacy and comparison with other dopamine agonists.
Albanese A; Colosimo C
Acta Neurol Scand; 2003 May; 107(5):349-55. PubMed ID: 12713527
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.
Dooley M; Markham A
Drugs Aging; 1998 Jun; 12(6):495-514. PubMed ID: 9638397
[TBL] [Abstract][Full Text] [Related]
20. Combination of two different dopamine agonists in the management of Parkinson's disease.
Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
